Roy B. Tishler, MD, PhD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 632-3591
Fax: (617) 632-4247


roy_tishler@dfci.harvard.edu

Roy B. Tishler, MD, PhD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Associate Professor, Radiation Oncology, Harvard Medical School
  • Assistant Professor, Radiation Oncology Department, Dana-Farber Cancer Institute

Research Abstract

My laboratory research focuses on the molecular mechanisms of interaction of radiation and chemotherapeutic drugs, particularly the taxanes. Current projects are examining the role of the tumor suppressor p53 and bcl-2 related proteins on the interaction of Taxol and radiation in human tumor cells. We are also examining other chemotherapy-radiaton interactions, as well as different aspects of radiation-dependent gene induction. My clinical reasearch interests are: 1) use of combined modality treatment for organ preservation in the treatment of head and neck cancers 2) role of radiation sensitizers and chemotherapeutic drugs in treatment of tumors of the central nervous system.

Publications

Powered by Harvard Catalyst
  • Keane FK, Chen YH, Neville BA, Tishler RB, Schoenfeld JD, Catalano PJ, Margalit DN. Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era. Cancer 2015. PubMed
  • Margalit DN, Losi SM, Tishler RB, Schoenfeld JD, Ann Fugazzotto J, Stephens J, Cebulski AL, Hammerstrand EL, Ma L, Lopes HM, Haddad RI, Treister NS, Frustino JL. Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Oncol Pract 2015; 11:151-4. PubMed
  • Tishler RB. Increased clarity on the use of radiotherapy in the management of desmoplastic melanoma. Cancer 2014; 120:1315-8. PubMed
  • Michaelson EM, Chen YH, Silver B, Tishler RB, Marcus KJ, Stevenson MA, Ng AK. Thyroid malignancies in survivors of Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2014; 88:636-41. PubMed
  • Chapuy CI, Annino DJ, Tishler RB, Haddad RI, Snavely A, Goguen LA. Success of endoscopic pharyngoesophageal dilation after head and neck cancer treatment. Laryngoscope 2014; 123:3066-73. PubMed
  • Misiukiewicz KJ, Camille N, Tishler R, Haddad R, Limaye S, Posner M. Organ Preservation for Adenoid Cystic Carcinoma of the Larynx. Oncologist 2013. PubMed
  • Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 2013; 14:257-64. PubMed
  • Limaye SA, Posner MR, Krane JF, Fonfria M, Lorch JH, Dillon DA, Shreenivas AV, Tishler RB, Haddad RI. Trastuzumab for the treatment of salivary duct carcinoma. Oncologist 2013; 18:294-300. PubMed
  • Sher DJ, Posner MR, Tishler RB, Sarlis NJ, Haddad RI, Holupka EJ, Devlin PM. Relationship Between Radiation Treatment Time and Overall Survival After Induction Chemotherapy for Locally Advanced Head-and-Neck Carcinoma: A Subset Analysis of TAX 324. Int J Radiat Oncol Biol Phys 2011. PubMed
  • Sher DJ, Balboni TA, Haddad RI, Norris CM, Posner MR, Wirth LJ, Goguen LA, Annino D, Tishler RB. Efficacy and Toxicity of Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Unknown Primary of Head and Neck. Int J Radiat Oncol Biol Phys 2010. PubMed
  • Schoenfeld JD, Sher DJ, Norris CM, Haddad RI, Posner MR, Balboni TA, Tishler RB. Salivary Gland Tumors Treated With Adjuvant Intensity-Modulated Radiotherapy With or Without Concurrent Chemotherapy. Int J Radiat Oncol Biol Phys 2010. PubMed
  • Sher DJ, Haddad RI, Norris CM, Posner MR, Wirth LJ, Goguen LA, Annino D, Balboni T, Allen A, Tishler RB. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer 2010; 116:4761-8. PubMed
  • Goguen LA, Chapuy CI, Sher DJ, Israel DA, Blinder RA, Norris CM, Tishler RB, Haddad RI, Annino DJ. Utilizing computed tomography as a road map for designing selective and superselective neck dissection after chemoradiotherapy. 2010; 143:367-74. PubMed
  • Goguen LA, Norris CM, Jaklitsch MT, Sullivan CA, Posner MR, Haddad RI, Tishler RB, Burke E, Annino DJ. Combined antegrade and retrograde esophageal dilation for head and neck cancer-related complete esophageal stenosis. Laryngoscope 2010; 120:261-6. PubMed
  • Marcus KJ, Tishler RB. Head and neck carcinomas across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol 2009; 20:52-7. PubMed
  • Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P, Allen A, Mahadevan A, Flynn J, Burke E, Li Y, Tishler RB. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer 2009; 115:4514-23. PubMed
  • Haddad RI, Tishler RB, Norris C, Goguen L, Balboni TA, Costello R, Wirth L, Lorch J, Andreozzi B, Annino D, Posner MR. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:4448-53. PubMed
  • Chin DW,Treister N,Friedland B,Cormack RA,Tishler RB,Makrigiorgos GM,Court LE. Effect of dental restorations and prostheses on radiotherapy dose distribution: a Monte Carlo study. J Appl Clin Med Phys 2009; 10:2853. PubMed
  • Caglar HB, Tishler RB, Othus M, Burke E, Li Y, Goguen L, Wirth LJ, Haddad RI, Norris CM, Court LE, Aninno DJ, Posner MR, Allen AM. Dose to Larynx Predicts for Swallowing Complications After Intensity-Modulated Radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72:1110-8. PubMed
  • Court LE,Wolfsberger L,Allen AM,James S,Tishler RB. Clinical experience of the importance of daily portal imaging for head and neck IMRT treatments. J Appl Clin Med Phys 2008; 9:2756. PubMed
  • Haddad R, Annino D, Tishler RB. Multidisciplinary approach to cancer treatment: focus on head and neck cancer. Dent Clin North Am 2007; 52:1-17, vii. PubMed
  • Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705-15. PubMed
  • Court LE, Tishler RB. Experimental evaluation of the impact of different head-and-neck intensity-modulated radiation therapy planning techniques on doses to the skin and shallow targets. Int J Radiat Oncol Biol Phys 2007; 69:607-13. PubMed
  • Court LE, Allen A, Tishler R. Evaluation of the precision of portal-image-guided head-and-neck localization: an intra- and interobserver study. Med Phys 2007; 34:2704-7. PubMed
  • Allen AM, Haddad RI, Tishler RB. Retropharyngeal nodes in hypopharynx cancer on positron emission tomography. J Clin Oncol 2007; 25:599-601. PubMed
  • Goguen LA, Posner MR, Tishler RB, Wirth LJ, Norris CM, Annino DJ, Sullivan CA, Li Y, Haddad RI. Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2006; 132:526-31. PubMed
  • Colevas AD, Norris CM, Tishler RB, Fried MP, Gomolin HI, Amrein P, Nixon A, Lamb C, Costello R, Barton J, Read R, Adak S, Posner MR. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999; 17:3503-11. PubMed
  • Tishler RB, Busse PM, Norris CM, Rossi R, Poulin M, Thornhill L, Costello R, Peters ES, Colevas AD, Posner MR. An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. Int J Radiat Oncol Biol Phys 1999; 43:1001-8. PubMed
  • Colevas AD, Busse PM, Norris CM, Fried M, Tishler RB, Poulin M, Fabian RL, Fitzgerald TJ, Dreyfuss A, Peters ES, Adak S, Costello R, Barton JJ, Posner MR. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 1998; 16:1331-9. PubMed
  • Clark JR, Busse PM, Norris CM, Andersen JW, Dreyfuss AI, Rossi RM, Poulin MD, Colevas AD, Tishler RB, Costello R, Lucarini JW, Lucarini D, Thornhill L, Lackey M, Peters E, Posner MR. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. J Clin Oncol 1997; 15:3100-10. PubMed
  • Tishler RB, Lamppu DM. The interaction of taxol and vinblastine with radiation induction of p53 and p21 WAF1/CIP1. Br J Cancer Suppl 1996; 27:S82-5. PubMed
  • Tishler RB, Lamppu DM, Park S, Price BD. Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res 1995; 55:6021-5. PubMed
  • Tishler RB, Calderwood SK, Coleman CN, Price BD. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 1993; 53:2212-6. PubMed
  • Tishler RB, Geard CR, Hall EJ, Schiff PB. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992; 52:3495-7. PubMed
  • Tishler RB, Geard CR. Correlation of sensitizer enhancement ratio with bromodeoxyuridine concentration and exposure time in human cervical carcinoma cells treated with low dose rate irradiation. Int J Radiat Oncol Biol Phys 1992; 22:495-8. PubMed
  • Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992; 22:613-7. PubMed
  • Tishler RB, Geard CR. Low dose rate irradiation and halogenated pyrimidine effects on human cervical carcinoma cells. Int J Radiat Oncol Biol Phys 1991; 21:975-82. PubMed
Hide